Strategic Licensing Agreement for Rare Disease Treatments

THX Pharma and Biocodex have entered a strategic licensing agreement to develop and commercialize treatments for three rare diseases. Biocodex will acquire licenses to Batten-1 globally and TX01 in the U.S. and Canada, valued up to €173 million, including a €12 million upfront payment and milestone payments.

Batten-1 targets juvenile Batten disease, while TX01 addresses Gaucher disease and Niemann-Pick disease type C. These rare, genetically inherited disorders primarily affect children, leading to severe impairments and a lack of effective treatments.

THX Pharma will handle clinical development, with Biocodex managing market access and commercialization. This collaboration emphasizes the commitment of both companies to fill unmet medical needs through innovative therapeutic solutions.